Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials

por Ceresoli, G L, Castagneto, B, Zucali, P A, Favaretto, A, Mencoboni, M, Grossi, F, Cortinovis, D, Conte, G Del, Ceribelli, A, Bearz, A, Salamina, S, De Vincenzo, F, Cappuzzo, F, Marangolo, M, Torri, V, Santoro, A
Publicado 2008

A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors

por Grilley-Olson, J. E., Bedard, P. L., Fasolo, A., Cornfeld, M., Cartee, L., Razak, A. R. Abdul, Stayner, L.-A., Wu, Y., Greenwood, R., Singh, R., Lee, C. B., Bendell, J., Burris, H. A., Conte, G. Del, Sessa, C., Infante, J. R.
Publicado en Invest New Drugs (2016)